STOCK TITAN
  1. Home
  2. News
  3. TVTX

Travere Therapeutics Inc - TVTX STOCK NEWS

Welcome to our dedicated news page for Travere Therapeutics (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Travere Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Travere Therapeutics's position in the market.

News
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Rhea-AI Summary
Travere Therapeutics presents research on pegtibatinase as a potential treatment for classical homocystinuria at upcoming medical conferences. The Company will showcase trial designs, innovative tools for dietary management, and positive results from previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
-
News
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) to present nine abstracts at upcoming conferences, showcasing FILSPARI's potential as a foundational treatment for IgAN. The data include subgroup analyses, preliminary findings, and insights on disease management, highlighting the Company's commitment to innovation in rare kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
-
News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Travere Therapeutics, Inc. (NASDAQ: TVTX) granted 51,600 inducement equity grants to four new employees on March 10, 2024. The grants include 25,000 stock options and 26,600 restricted stock units outside the 2018 Equity Incentive Plan. The stock options have an exercise price of $7.99 per share, a 10-year term, and vest over four years. The RSUs also vest over four years, with 25% of shares vesting on each anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.61%
Tags
none
News
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Rhea-AI Summary
Travere Therapeutics, Inc. submits sNDA to FDA for full approval of FILSPARI in IgA nephropathy based on positive 2-year Phase 3 PROTECT Study results, showing significant reduction in proteinuria and kidney function preservation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
none
-
News
Travere Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) will participate in upcoming investor conferences in March 2024. The company will be present at Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference. Live webcasts of the presentations will be available on Travere's investor page, with replays accessible for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
conferences
-
News
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
Rhea-AI Summary
The CHMP recommends conditional marketing authorization for sparsentan in Europe for the treatment of IgA nephropathy, a rare kidney disorder. If approved, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for IgAN patients. The decision is expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
News
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Travere Therapeutics reports strong financial results for Q4 2023 with 459 new patient start forms for FILSPARI, nearing sNDA submission for full approval in the US, CHMP opinion expected in Europe, and Phase 3 HARMONY Study progress. Net product sales reached $39.9 million for Q4 and $127.5 million for FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
earnings
-
News
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) will report its Q4 and full year 2023 financial results on February 15, 2024. The company will host a conference call and webcast to discuss the financial results and provide a general business update. The webcast and dial-in information can be accessed on the Investor page of Travere’s website. An archived version of the call will be available for 30 days on the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences earnings
-
News
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) will present at the Guggenheim 6th Annual Biotechnology Conference on February 8, 2024, at 11:30 a.m. ET. The presentation will be accessible via live webcast and a replay will be available for 30 days. Investors can watch the webcast on the Investor page of Travere’s website at ir.travere.com/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
News
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Rhea-AI Summary
Travere Therapeutics, Inc. has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia. Renalys will hold regional rights to sparsentan for Japan, South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Travere will receive an upfront payment and be eligible to receive up to $120 million in regulatory, development, and sales-based milestone payments. Results from the urine protein/creatinine ratio (UP/C) endpoint in the study are expected in the second half of 2025 to support a submission for approval to PMDA. Travere has obtained a minority equity stake in Renalys and will be eligible to receive tiered royalties on net sales of sparsentan in Japan, South Korea, Taiwan, and the specified Southeast Asian nations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
none
Stock TVTX logo
Travere Therapeutics Inc

Nasdaq:TVTX

TVTX Rankings

#3062 Ranked by Market Cap
#5106 Ranked by Stock Gains
N/A Ranked by Dividends

TVTX Stock Data

484.81M
60.60M
0.65%
115.18%
13.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego